Full Press Release Details
to Supply Rare Cannabinoids to Radicle
Science's "Radicle Energy Study" to Assess the
Health Effects of THCV
Vancouver, BC and South San Francisco, CA -
May 05, 2022 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the
research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce that its subsidiary, BayMedica,
will be providing rare cannabinoids for use in Radicle Science, Inc.'s Radicle Energy rare cannabinoid study to assess the effects
of delta-9 ("d-9") dominant tetrahydrocannabivarin ("THCV") on energy, focus/attention, appetite and weight/BMI.
BayMedia will be supplying its highly pure d-9 dominant THCV, formulated into a proprietary lozenge manufactured by Trokie.
rare cannabinoid, consumer-based investigation will measure the effects of the Company's d-9 dominant THCV in a randomized, blinded,
placebo-controlled study in up to 900 adult participants aged 21 and older who reside in the United States. The
study includes three dosing groups including a placebo group (no THCV), each delivered via Trokie's proprietary lozenge technology.
The study is set to begin participant recruitment in May and will run for a four week period starting in June with results expected during
the summer. The study is part of Radicle Science's large scale investigations into several rare cannabinoids involving up to 10,000
participants in total, the largest of its kind to date.
"We are excited to be part of this groundbreaking
study with Trokie and Radicle Science in advance of our commercial launch of d-9 dominant THCV. Radicle Science has been at the forefront
of cannabinoid research, providing much needed scientific evidence to validate the effects of cannabinoids, and Trokie is a leader in
unique and effective delivery systems for cannabinoids," said Dr. Shane Johnson, SVP and General Manager of BayMedica. "As
a company driven by data and science, independent third-party research provides important information as we continue to expand our product
portfolio of rare cannabinoids for the health and wellness market. Evidence-based decision making is key to facilitate adoption of rare
cannabinoids by consumers, brands and healthcare providers. This research will advance the understanding of rare cannabinoids, which have
been historically under-investigated."
Dr. Emily Pauli, Pharm.D, Chief Research Officer
of Radicle Science, added, "Consumers have been reporting anecdotal benefits from THCV; but, to date, we have sparse evidence on
it and other rare cannabinoids. We look forward to analyzing the results of this inaugural study of THCV, which is the first of its kind
in a consumer-driven setting. With the large number of participants, we can assess whether there are meaningful improvements with energy
and focus, as well as any impact on appetite. With our innovative AI-enabled approach, we can study diverse Americans across the country
- which may also reveal personalized factors that impact the effect of THCV."
"This study continues Trokie's commitment
to developing products based on scientific evidence and rigorous standards" said Gavin Chandler, CFA, CEO and President of Trokie.
"The Radicle Science Discovery platform is the gold standard in the health and wellness industry for understanding how cannabinoid
products can provide health benefits across many different populations. We are excited to partner with BayMedica on this study, with their
differentiated rare cannabinoids of exceptional quality and purity, which matches our product philosophy." Trokie's Advisory
Board member, Jordan Tishler, MD, President of the Association of Cannabinoid Specialists and faculty at Harvard Medical School, added,
"The Radicle Energy study will significantly add to the body of knowledge regarding the health effects of lesser known cannabinoids
like THCV. The combination of Trokie's novel delivery system, BayMedica's high purity cannabinoids, and Radicle's Discovery
study platform provide an excellent opportunity to learn more about how these products can improve human health."
BayMedica - We do cannabinoids differently
BayMedica manufactures rare cannabinoids through
novel synthetic methods that ensure reproducible quality and purity. The Company's products are manufactured under food-grade GMP
(Good Manufacturing Practice) standards for the health and wellness sector, and are bioidentical to plant-derived compounds. These cannabinoids
can be custom formulated for a variety of consumer health and wellness applications including supplements, nutraceuticals, cosmetics and
animal health. Utilizing reproducible processes guarantee the purity and consistency of our cannabinoids each and every time. Furthermore,
these production methods can be scaled up to meet demand to ensure that clients have an ongoing source of cannabinoids without supply
chain concerns. BayMedica has large scale batches of cannabidivarin ("CBDV"), cannabichromene ("CBC") and
cannabicitran ("CBT") available for wholesale purchase and will be commencing B2B sales of d-9 dominant tetrahydrocannabivarin
Tetrahydrocannabivarin, also known as THCV, or
d9-THCV, is a naturally occurring compound of the Cannabis sativa plant, and is an analog of the better known major cannabinoid,
tetrahydrocannabinol ("THC"). While these two cannabinoids share a similar structure and name, they have very different physiological
effects. Notably, unlike THC which is intoxicating and produces a "high" or euphoric effect, and is a scheduled
compound that is federally illegal unless prescribed by a physician, THCV is non-intoxicating and is not a scheduled compound.
Learn more about InMed's Cannabinoids in Development: https://www.inmedpharma.com/pharmaceutical/cannabinoids-in-development/
Learn more about BayMedica's THCV: https://www.baymedica.com/tetrahydrocannabivarin-thcv/
Learn more about BayMedica's CBC: https://www.baymedica.com/cannabichromene-cbc/
InMed Pharmaceuticals
is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary
BayMedica, LLC, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including
pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics
and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more
information, visit www.inmedpharma.com and www.baymedica.com.
Radicle Science is an AI-driven healthtech B-corp offering the first ever scalable path to validate and predict the
effects of health and wellness products, transforming them into democratized precision solutions for ailments or enhancement of human
function. Radicle Science leverages a proprietary data analytics platform and a virtual, direct-to-consumer (D2C) clinical trial model
to deliver objective health outcome data across diverse populations and conditions-all at a fraction of the cost and time of traditional
methods. The Radicle Vision is a future where affordable, accessible health and wellness products are trusted by patients, recommended
by healthcare providers, reimbursed by insurance and used as widely as pharmaceutical drugs. Learn more at www.RadicleScience.com.
Senior Director, Investor Relations
Cautionary Note Regarding Forward-Looking Information:
This news release contains
"forward-looking information" and "forward-looking statements" (collectively, "forward-looking
information") within the meaning of applicable securities laws. Forward-looking information is based on management's current
expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Forward-looking information in this news release includes statements about:
providing rare cannabinoids for use in Radicle Science, Inc.'s Radicle Energy rare cannabinoid study to assess the effects of
delta-9 ("d-9") dominant tetrahydrocannabivarin ("THCV") on energy, focus/attention, appetite and
weight/BMI; supplying its highly pure d-9 dominant THCV, formulated into a proprietary lozenge
manufactured by Trokie; a consumer-based investigation will measure the effects of the
Company's d-9 dominant THCV in a randomized, blinded, placebo-controlled study in up to 900 adult participants aged 21 and
older who reside in the United States; a study includes three dosing groups including a placebo
group (no THCV), each delivered via Trokie's proprietary lozenge technology; a groundbreaking
study with Trokie and Radicle Science in advance of our commercial launch of d-9 dominant THC; Radicle
Science being at the forefront of cannabinoid research, providing much needed scientific
evidence to validate the effects of cannabinoids, and Trokie being a leader in unique and
effective delivery systems for cannabinoids; independent third-party research providing important
information as we continue to expand our product portfolio of rare cannabinoids for the health and wellness market; evidence-based
decision making being key to facilitate adoption of rare cannabinoids by consumers, brands and
healthcare providers; research that will advance the understanding of rare cannabinoids, which
have been historically under-investigated; analyzing the results of this inaugural study of
THCV, which is the first of its kind in a consumer-driven setting; a large number of
participants, we can assess whether there are meaningful improvements with energy and focus, as well as any impact on
appetite; an innovative AI-enabled approach, we can study diverse Americans across the country
- which may also reveal personalized factors that impact the effect of THCV; developing
products based on scientific evidence and rigorous standards; The Radicle Science Discovery
platform is the gold standard in the health and wellness industry for understanding how cannabinoid products can provide health
benefits across many different populations; differentiated rare cannabinoids of exceptional
quality and purity; significantly add to the body of knowledge regarding the health effects of
lesser known cannabinoids like THCV; combination of Trokie's novel delivery system,
BayMedica's high purity cannabinoids, and Radicle's Discovery study platform provide an excellent opportunity to learn